Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Sunil Asnani"'
Publikováno v:
Comprehensive Therapy. 28:200-206
The thiazolidinediones are the insulin sensitizers used in the management of Type 2 diabetes mellitus. These drugs can potentially decrease the risk of cardiovascular disease by correcting the different components of the insulin resistance syndrome.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06df52184ce6e772ecbf05dd2433abf3
https://doi.org/10.1007/s12019-002-0018-8
https://doi.org/10.1007/s12019-002-0018-8
Publikováno v:
The Endocrinologist. 12:126-134
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3b3c2fa2719ed382fb7103dc3bf69de
https://doi.org/10.1097/00019616-200203000-00011
https://doi.org/10.1097/00019616-200203000-00011
Publikováno v:
American Journal of Cardiovascular Drugs. 2:149-156
Rosiglitazone and pioglitazone are medications from the thiazolidinedione class of compounds currently available for the treatment of type 2 diabetes mellitus. Traditionally used to enhance insulin sensitivity and decrease plasma insulin levels, adde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e990a6998452fc50349122a57a6cff0b
https://doi.org/10.2165/00129784-200202030-00002
https://doi.org/10.2165/00129784-200202030-00002
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 91:25-27
Type 2 diabetes is associated with an increased risk of cardiovascular events that carry a poor prognosis. People with diabetes have not benefited to the same degree as those without diabetes in terms of recent reductions in cardiovascular mortality.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::743b6882d105a6d0da8273422b2c67be
https://doi.org/10.1210/jc.2005-2450
https://doi.org/10.1210/jc.2005-2450
Publikováno v:
Metabolic syndrome and related disorders. 1(2)
Hyperhomocysteinemia is a well-established risk factor for cardiovascular disease. The association of hyperhomocysteinemia with diabetes mellitus is complex and may explain some of the risk of CVD in diabetics not explained by traditional risk factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b88cb22984fbaf1ddd215559bbe8497
https://pubmed.ncbi.nlm.nih.gov/18370636
https://pubmed.ncbi.nlm.nih.gov/18370636
Publikováno v:
Metabolic syndrome and related disorders. 4(3)
The primary aim of this study was to evaluate the effect of pioglitazone on endothelial function, as assessed by flow-mediated dilatation (FMD) nitroglycerine-induced dilatation (NID) in patients with type 2 diabetes mellitus treated with insulin. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d2449304d760639c7d58052840d0569
https://pubmed.ncbi.nlm.nih.gov/18370736
https://pubmed.ncbi.nlm.nih.gov/18370736
Publikováno v:
Metabolic syndrome and related disorders. 1(1)
Peroxisome proliferator–activated receptors (PPARs) are members of the nuclear receptor superfamily comprising four subtypes designated PPARa, PPARg1, PPARg2, and PPARd. These are transcription factors that regulate gene expression, thereby control
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62eed12ed9a82fc019605653fafee0c8
https://pubmed.ncbi.nlm.nih.gov/18370623
https://pubmed.ncbi.nlm.nih.gov/18370623
Publikováno v:
Journal of diabetes and its complications. 22(5)
Type 2 diabetes mellitus (T2DM) with microalbuminuria (MA) is associated with increased risk of cardiovascular events (CVE) that may be attenuated by angiotensin-converting enzyme inhibitors (ACEIs), unless microalbuminuria persists (PMA). African-Am
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38fd928d875eb3a4ac104536af74c6a4
https://pubmed.ncbi.nlm.nih.gov/18413195
https://pubmed.ncbi.nlm.nih.gov/18413195
Publikováno v:
The Journal of clinical endocrinology and metabolism. 91(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::35dd86863b00f1bf1d37c0e9e834d0e8
https://pubmed.ncbi.nlm.nih.gov/16303829
https://pubmed.ncbi.nlm.nih.gov/16303829